Vincristine/irinotecan upfront window treatment of high-risk hepatoblastoma: A report from the Children’s Oncology Group (COG) AHEP0731 study committee.

Katzenstein, Howard M.; Furman, Wayne L.; Malogolowkin, Marcio H.; Krailo, Mark; McCarville, M. Beth; Towbin, Alexander J.; Tiao, Greg; Finegold, Milton J.; Ranganathan, Sarangarajan; Dunn, Stephen P.; Langham, Max R.; McGahren, Eugene D.; Rodríguez‐Galindo, Carlos; Meyers, Rebecka L.

doi:10.1200/jco.2016.34.15_suppl.10516

Cited by 3 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We show that the incidence of HB and survival has increased over the past two decades in the United States, disparities in survival exist by age, race or ethnicity, and stage, and improvements in survival after 2009 may reflect systematic changes in therapy introduced to the field 1,8–12 . Our study differs from prior studies in that it utilizes databases that include between 100% and 94% of pediatric HB cases during the study period, allowing for comprehensive analysis of recent trends in incidence and survival outcomes, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…Lastly, the high‐risk stratum enrolled patients with any Stage IV disease or any stage HB with the initial alpha‐fetoprotein level <100 ng/ml. The treatment of high‐risk patients included an investigational upfront window containing two cycles of VCR and irinotecan (VI) and later with the addition of temsirolimus (VIT) followed by CDDP, VCR, 5FU, and DOX for six cycles with an additional two cycles of VI or VIT for patients with response to the upfront window 12 . PRETEXT 3 extensive multifocal, PRETEXT 3 +V, PRETEXT 3 +P, or PRETEXT 4 extensive multifocal tumors were candidates for orthotopic liver transplantation 10 .…”

Section: Discussionmentioning

confidence: 99%

“…In 2008, the Children's Oncology Group (COG) established a risk‐based treatment approach for HB with the AHEP0731 protocol 1,8–12 . This approach involves surgical resection and chemotherapy informed by a hybrid staging method incorporating the Evans staging system and tumor histology paired with updated chemotherapeutic and surgical strategy for each risk group 1,8–12 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Incidence and 5‐year survival of children and adolescents with hepatoblastoma in the United States

Kahla

Siegel

Dai³

et al. 2022

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Objective: Hepatoblastoma (HB) is the most common pediatric primary malignant liver tumor, its incidence has been increasing worldwide, but recent changes in incidence and outcomes with high population coverage are not well characterized. Methods: We defined the incidence of HB diagnosed during 2003-2017 from United States Cancer Statistics (USCS) database, and survival during 2001-2016 from the National Program of Cancer Registries (NPCR). Data were stratified by sex, race/ethnicity, age, tumor stage, county population, and diagnosis year. Incidence trends were assessed by calculating average annual percent change (AAPC) using Joinpoint regression. Differences in overall 5-year survival were estimated using Cox regression analysis.Results: 2178 HB cases with an annual incidence rate of 1.76 per million persons were identified and incidence increased over time (AAPC = 2.2, 95% confidence interval [CI], 0.9-3.6). The 5-year relative survival was 76.9% (95% CI: 74.9-78.8) and the risk of death was lower for cases diagnosed after 2009 (hazard ratio [HR] = 0.77, 95%

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Incidence and 5‐year survival of children and adolescents with hepatoblastoma in the United States

Kahla

Siegel

Dai³

et al. 2022

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

Mutational signature, cancer driver genes mutations and transcriptomic subgroups predict hepatoblastoma survival

Pire,

Hirsch,

Morcrette

et al. 2024

European Journal of Cancer

View full text Add to dashboard Cite

Notable response of a young adult with recurrent glioblastoma multiforme to vincristine-irinotecan-temozolomide and bevacizumab

Papageorgiou

Tsakatikas²,

Fioretzaki³

et al. 2020

Anti-Cancer Drugs

View full text Add to dashboard Cite

Glioblastoma multiforme is a malignant central nervous system (CNS) disease with dismal prognosis. Current treatment modalities only offer modest activity and usually of short duration, so there is an urgent need for the conduct of clinical trials exploring new treatment options and modalities. The vincristine-irinotecan-temozolomide and bevacizumab (VITb) regimen is an option of special interest, as it has produced encouraging results in young patients with various relapsed/refractory childhood and adolescence solid tumors, with an acceptable toxicity profile. With the current report, we present the case of a young male patient who was treated for GBM in second relapse at out institution, after previous surgical attempts and two radiotherapy sessions in conjunction with temozolomide and experienced a major and long-lasting response, weaned off steroids, to the VITb regimen followed by bevacizumab maintenance. The above case is discussed in the context of the existing literature regarding available evidence of synergy between the drugs used and the activity of certain components of the combination (i.e. combination of temozolomide-irinotecan ± vincristine, or bevacizumab-irinotecan in GBM) or the complete VITb regimen in other pediatric/adolescence solid tumors and the few cases reported with GBM.

show abstract

Vincristine/irinotecan upfront window treatment of high-risk hepatoblastoma: A report from the Children’s Oncology Group (COG) AHEP0731 study committee.

Cited by 3 publications

References 22 publications

Incidence and 5‐year survival of children and adolescents with hepatoblastoma in the United States

Incidence and 5‐year survival of children and adolescents with hepatoblastoma in the United States

Mutational signature, cancer driver genes mutations and transcriptomic subgroups predict hepatoblastoma survival

Notable response of a young adult with recurrent glioblastoma multiforme to vincristine-irinotecan-temozolomide and bevacizumab

Contact Info

Product

Resources

About